Compare CWCO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | EDIT |
|---|---|---|
| Founded | 1973 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 432.8M |
| IPO Year | 1997 | 2016 |
| Metric | CWCO | EDIT |
|---|---|---|
| Price | $28.68 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $5.30 |
| AVG Volume (30 Days) | 104.9K | ★ 2.7M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | $31,937,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | $124.65 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $28.17 | $1.66 |
| 52 Week High | $39.12 | $4.54 |
| Indicator | CWCO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 72.77 |
| Support Level | $28.70 | $1.93 |
| Resistance Level | $30.69 | $3.94 |
| Average True Range (ATR) | 0.71 | 0.25 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 10.64 | 96.93 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.